98%
921
2 minutes
20
Background: A novel focal lattice-tip catheter allowing the delivery of either pulsed field (PF) or radiofrequency (RF) energy has recently received regulatory approval. The technology features a proprietary 3-dimensional electroanatomic mapping system.
Objective: We describe the first real-world and multicenter experience.
Methods: Consecutive AF patients undergoing first-time or redo atrial tachyarrhythmia ablation with the Affera system were prospectively enrolled at 3 different centers. PF was the only energy source allowed when ablating the posterior left atrium; anterior applications were performed with either RF (PF/RF strategy) or PF (PF/PF strategy) on the basis of the operator's preference. The primary efficacy end point included acute electrical isolation of pulmonary veins and posterior wall or bidirectional block in case of linear lesions.
Results: The study included 130 patients (mean age, 67 ± 10 years; 63.8% [n = 83] male; 61.5% [n = 80] nonparoxysmal AF; 55.4% first-time AF ablation). First-time pulmonary vein isolation was performed in 72 patients: RF/PF in 13 (18.1%) patients and PF/PF in the remaining 59 (81.9%); first-pass isolation for pulmonary vein and posterior wall was achieved in 100% of cases. A total of 289 ablation lines were performed (roof line, 91 patients; inferior line, 83 patients; anterior mitral line, 32 patients; posterior mitral line, 45 patients; cavotricuspid isthmus line, 38 patients). First-pass isolation and primary efficacy end point were 96.2% (roof line, 100%; inferior line, 100%; anterior mitral line, 96.9%; posterior mitral line, 84.4%; cavotricuspid isthmus, 92.1%) and 100%, respectively. We had 2 (1.5%) major complications: 1 ST-segment elevation at the inferolateral leads requiring intracoronary administration of nitrate and 1 complete atrioventricular block.
Conclusion: Catheter ablation with a novel 9-mm lattice-tip catheter confirmed high efficacy and safety in a real-world scenario.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.hrthm.2024.12.021 | DOI Listing |
J Interv Card Electrophysiol
September 2025
Cardiac Ablation Solutions, Medtronic, Minneapolis, MN, USA.
Background: Catheter ablation is beneficial in patients with symptomatic persistent atrial fibrillation (PerAF), and pulsed field ablation (PFA) is a promising energy source to safely and durably create ablation lesions. However, catheter-specific "PFA waveforms and designs" result in effectiveness and safety profiles that are not transferable to other PFA technologies. A head-to-head comparison between the dual-energy, wide-footprint lattice-tip (Sphere-9, Medtronic) and pentaspline PFA catheter (Farawave, Boston Scientific) is not yet available.
View Article and Find Full Text PDFEuropace
September 2025
Department of Cardiology and Vascular Medicine, University Heart and Vascular Center Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
Background And Aims: Aim of this study was to assess the risk of hemolysis, the extent of myocardial and neural injury after monopolar, monophasic pulsed field ablation (PFA) using a lattice-tip catheter in comparison to single-shot PF ablation platforms employing bipolar, biphasic waveforms.
Methods: This prospective study included consecutive patients undergoing PFA for atrial fibrillation (AF) using the Affera™ mapping and ablation system (n=40). Biomarkers for hemolysis (haptoglobin, LDH, bilirubin), myocardial injury (high-sensitive troponin T, CK, CK-MB), neurocardiac injury (S100), and renal function (creatinine) were assessed pre- and within 24 hours post-ablation.
Europace
August 2025
Northwell Cardiovascular Institute, Center for Arrhythmias, New Hyde Park, NY.
Background And Aims: Renal failure due to intravascular hemolysis (IH) has been reported after pulsed field ablation (PFA) of atrial fibrillation (AF). However, IH incidence using the accepted laboratory criteria is unknown.
Methods: In this prospective observational study (Sept 2024-May 2025), consecutive patients undergoing PFA for AF with pentaspline (PS), circular array (CA), or lattice-tip (LT) catheters were included.
J Cardiovasc Electrophysiol
August 2025
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Introduction: Pulsed-field ablation (PFA) is an emerging technology associated with dose-dependent hemolysis as a recently recognized side effect. This study aimed to compare hemolysis levels and assess dose-dependency across three PFA systems: a pentaspline catheter (PSC), a lattice-tip focal catheter (LTFC), and a variable loop circular catheter (VLCC).
Methods: Patients treated for atrial arrhythmias with the LTFC (n = 29) or the VLCC (n = 30) were included from a prospective registry.
J Invasive Cardiol
August 2025
Cleveland Clinic, Cleveland, Ohio.
Objectives: Increasing atrial fibrillation (AF) disease-related healthcare burden, coupled with positive evidence on catheter ablation for AF, has led to pressure on hospital procedure efficiency. Medtronic's Sphere-9 system (a novel lattice-tip dual-energy pulsed field and radiofrequency [RF] ablation catheter) demonstrated non-inferiority in effectiveness and superiority in procedural times compared with a contact-force sensing RF catheter (ThermoCool SmartTouch SF [STSF]). This analysis evaluated the impact of procedural efficiencies on electrophysiology (EP) lab utilization.
View Article and Find Full Text PDF